Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$19.78
-$0.20(-2.99%)
At close: 4:00 PM EST
$19.78
-$0.20(-2.99%)
Day’s Range― - ―
52-Week Range$3.51 - $25.77
Previous CloseN/A
Volume283.19K
Average Volume (3M)1.15M
Market Cap
$1.46B
Enterprise Value$1.20B
Total Cash (Recent Filing)$377.10M
Total Debt (Recent Filing)$39.19M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 07, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding80,015,670
10 Day Avg. Volume836,939
30 Day Avg. Volume1,148,653
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)5.59
Price to Sales (P/S)10.53
P/FCF Ratio-47.37
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue9.68
Enterprise Value/Gross Profit10.02
Enterprise Value/Ebitda-27.76
Forecast
1Y Price Target
$31.50Price Target Upside59.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$56.75M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsMolecular glue candidates produced meaningful biomarker reductions and confirmed prostate-specific antigen responses in patients with androgen receptor mutations, indicating early signs of clinical activity in inflammatory and prostate cancer indications.
Safety And Tolerability ProfilePhase 1 unblinded data reported no serious or high-grade adverse events and overall adverse event rates lower in treated subjects than in placebo, supporting a tolerability profile favorable for combination regimens.
Strategic Collaborations And Development PathwayCollaborations with major pharmaceutical partners and a clinical supply agreement enable planned Phase 2 combination studies and broaden development options, including a focused program for metastatic castration-resistant prostate cancer.
Bears Say
Data Robustness And Trial SizeAvailable clinical data come from a small patient group, which limits confidence in results and necessitates substantially larger trials to validate efficacy and safety.
Financing RiskHigh cash burn relative to available cash creates a material financing risk that could require additional funding and potentially dilute shareholders.
Market Skepticism And Analyst CautionNotable short interest and suspended analyst price targets reflect meaningful investor skepticism about the near-term prospects and the clarity of the path to market.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $3.51 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $1.46B.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 18 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Mar 17, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.188.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is -0.38.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 80,015,670 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went down -1.957%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (59.25% Upside)
$31.50 (59.25% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $891.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
334.72%
12-Months-Change
Fundamentals
Return on Equity
-15.12%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$31.50
▲(59.25% Upside)
Technical Analysis
CytomX Therapeutics
―
Fulcrum Therapeutics
―
Monopar Therapeutics Inc
―
―
Inhibrx Biosciences Inc
―
Ownership Overview
10.58% Insiders
12.48% Mutual Funds
0.05% Other Institutional Investors
60.22% Public Companies and
Individual Investors